Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain

Ziakas, Panayiotis D.

doi:10.3324/haematol.12970

Cited by 68 publications

(48 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…26 A meta-analysis on 17 studies that included 2,905 patients showed that the presence of the JAK2 V617F mutation was associated with an increased risk of both venous and arterial thrombosis in patients with essential thrombocythemia. 27 Similar results were published in a retrospective multicenter study involving 239 patients with ET. In that study, previous thrombotic history and the JAK2 V617F mutation were connected to an increased 10-year cumulative rate of thrombohemorrhagic events.…”

Section: Essential Thrombocythemia (Et) Is Manifested Clinical-supporting

confidence: 78%

Acute Coronary Syndromes in Patients with Hematological Disorders

Benedek

Lázár

Sándor-Kéri

et al. 2016

Journal of Cardiovascular Emergencies

View full text Add to dashboard Cite

Hematological conditions can lead to serious disturbances in blood rheology, being frequently associated with increased systemic inflammation and increased risk of bleeding. The imbalance between coagulation and thrombolytic factors in patients with acute coronary syndromes may lead to undesirable outcomes, and the success of emergency coronary angioplasty or by-pass grafting may be altered by increased bleeding in coagulopathies such as hemophilia. This paper intends to review the present knowledge in the field of acute coronary syndromes in subjects with hematological and onco-hematological disorders such as thrombotic thrombocytopenic purpura, immune thrombocytopenic purpura, von Willebrand disease, hemophilia, polycythemia vera, erythrocyte disorders, myelodysplastic syndrome, leukemia, lymphoma or myeloma.

show abstract

Section: Essential Thrombocythemia (Et) Is Manifested Clinical-supporting

confidence: 78%

Acute Coronary Syndromes in Patients with Hematological Disorders

Benedek

Lázár

Sándor-Kéri

et al. 2016

Journal of Cardiovascular Emergencies

View full text Add to dashboard Cite

show abstract

“…The role of JAK2 V617F , mutation as independent factor for thrombosis is still debated [7,[16][17][18][19][20]. In our series, we did not find any significant role of JAK2 V617F for predicting thrombosis, but some limit of our analysis should be considered because we cannot exclude that this may reflect an inadequate sample size.…”

Section: Discussionmentioning

confidence: 55%

Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms

et al. 2009

View full text Add to dashboard Cite

International audienceThe evidence that leukocytes may contribute to the pathogenesis of thrombosis in Chronic Myeloproliferative Neoplasms is increasing but not definitive. To further enforces whether an increased leukocyte count is associated with thrombosis and whether this effect can be modulated by cytoreductive therapy, we analyzed the clinical course of 187 patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) followed at two Italian Institutions over a period of 7 years. The association was measured at diagnosis or before thrombotic events: a multivariable analysis was carried out using data at baseline and time-dependent covariates. We found that white blood cells (WBC) count above 9.5 × 10/L at diagnosis (baseline analysis) was associated with thrombosis during the follow-up (Hazard Ratio [HR] of 1.8, 0.03). At the time-dependent analysis, therapy with hydroxyurea (HU), lowering by 35% the baseline WBC level, reduced such strength of association giving a HR of 1.3 ( value non significant). We found a trend between WBC level and thrombosis in untreated low-risk patients (RR of 1.9, 95% CI 0.9 to 3.1); in high-risk patients treated with HU this correlation was clearly lost (RR 1.1, 95% CI 0.2 to 2.7). Finally, we could not identify the presence of as a risk factor for thrombosis. Properly designed prospective studies should corroborate such results

show abstract

“…According to knowledge from analyses done in the past era of the PVSG classification [7], older age ( 60 years) and a history of thrombosis are considered as standard risk factors for thrombosis and guide current treatment decisions [11]. Leukocytosis at diagnosis and the JAK2V617F mutation are suspected as novel disease-associated risk factors for vascular complications [12][13][14]. Recently, the first data on risk factors for thrombosis in WHO-ET were released.…”

Section: Discussionmentioning

confidence: 99%

Leukocytosis as an important risk factor for arterial thrombosis in WHO‐defined early/prefibrotic myelofibrosis: An international study of 264 patients

et al. 2012

View full text Add to dashboard Cite

We aimed to determine risk factors for thrombotic events in early/prefibrotic myelofibrosis diagnosed according to the World Health Organization criteria. Multivariate Cox regression analysis was calculated on a total number of 264 patients derived from an international database. After a median follow‐up of 6.28 years, 42 (15.9%) patients experienced arterial (n = 31) or venous thrombosis (n = 11). A higher leukocyte count correlated with an increased risk for total thrombosis and in particular, with an increased risk for arterial thrombosis (P = 0.005, HR 1.15 and P = 0.047, HR 1.12, respectively). A platelet count above 870 × 109/L was associated with a lower risk for total thrombosis and also for venous thrombosis (P = 0.022, HR 0.44 and P = 0.027, HR 0.19). Moreover, a lower hemoglobin level was associated with an increased risk for venous thrombosis (P = 0.007, HR 0.59). Our data indicate that leukocytosis is a prominent risk factor for thrombosis in early/prefibrotic MF. Am. J. Hematol. 87:669–672, 2012. © 2012 Wiley Periodicals, Inc.

show abstract

Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain

Cited by 68 publications

References 24 publications

Acute Coronary Syndromes in Patients with Hematological Disorders

Acute Coronary Syndromes in Patients with Hematological Disorders

Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms

Leukocytosis as an important risk factor for arterial thrombosis in WHO‐defined early/prefibrotic myelofibrosis: An international study of 264 patients

Contact Info

Product

Resources

About